<DOC>
	<DOC>NCT01968720</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia. This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.</brief_summary>
	<brief_title>Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>Between 18 and 74 years at Screening Severe Hypertriglyceridemia (TG ≥ 500 mg/dL). If on lipid lowering therapy including statins, fibrates, and/or omega3 fatty acids, stable dose for at least 4 weeks prior to Screening Body mass index (BMI) ≤ 45 kg/m2 History of any major cardiovascular event within 6 months of Screening Type I diabetes mellitus or use of insulin History of pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>